UK Patent ‘Plausibility’: Landmark Lyrica Case May Get Supreme Court Ruling By Early Summer
Companies looking forward to a ruling from the Supreme Court on “plausibility” in the UK case involving second medical use patents may have to wait until May or June.
You may also be interested in...
A UK Supreme Court decision to invalidate Pfizer's pregabalin patent is not only bad news for Pfizer and good news for the generics firms involved – it could also mean that companies have to produce more evidence to substantiate their patent claims in future.
Pfizer execs say they are focused on commercial execution and pipeline development to drive growth. No viable buyer has emerged for the consumer business, CEO Read said.
Industry is eagerly awaiting this month’s judgement of the UK Supreme Court on whether a rule that constitutes a serious obstacle to enforcing patents for important medicines will be removed or modified, say legal experts Charlotte Tillett and Camille Arnold.